News
-
-
-
-
-
-
-
-
-
PRESS RELEASE
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Heidelberg Pharma advances into Cohort 7 with BCMA ATAC candidate HDP-101 targeting multiple myeloma, showing promising results and complete remission in Phase I/IIa study -